Biology of Langerhans Cells and Langerhans Cell Histiocytosis

Bechan, Gitanjali I.; Egeler, R. Maarten; Arceci, Robert J.

doi:10.1016/s0074-7696(06)54001-x

Cited by 70 publications

(54 citation statements)

References 235 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…1,2 It can follow a mild clinical course and even resolve spontaneously, 3,4 but it can also involve multiple organ systems with fatal consequences in 20% of disseminated cases. LCH's etiology is unknown.…”

Section: Introductionmentioning

confidence: 99%

Recurrent BRAF mutations in Langerhans cell histiocytosis

Badalian-Very

Vergilio

Degar

et al. 2010

Blood

1,047

841

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Recurrent BRAF mutations in Langerhans cell histiocytosis

Badalian-Very

Vergilio

Degar

et al. 2010

Blood

1,047

841

View full text Add to dashboard Cite

show abstract

“…[1][2][3] The disease has a broad spectrum of clinical behaviors, from a mild self-limited version to an aggressive form associated with a 20% mortality. Treatment has generally been empiric.…”

Section: Introductionmentioning

confidence: 99%

Somatic activating ARAF mutations in Langerhans cell histiocytosis

Nelson

Quispel

Badalian-Very

et al. 2014

Blood

157

102

View full text Add to dashboard Cite

“…By contrast, numerous genetic abnormalities, including the loss of heterozygosity, damage to the chromosomes and damage to genes (such as BRAF mutation), have been detected in LCH, which supports the possible clonal-expansive nature of the disease (22). These two pathways are currently under investigation with the aim to identify possible targets for the molecular therapy of LCH (10,14,15,(19)(20)(21)(23)(24)(25)(26)(27). One of the most exciting findings that may have therapeutical potential is the presence of the BRAF V600E mutation in LCH.…”

Section: Discussionmentioning

confidence: 99%

Langerhans cell histiocytosis with multisystem involvement in an infant: A case report

Sun

et al. 2015

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Abstract. Langerhans cell histiocytosis (LCH) is a proliferative disease of histiocyte-like cells, with a wide range of clinical presentations that vary from a solitary lesion to more severe multifocal or disseminated lesions. The disease can affect any age group; however, the peak incidence rate is in infants aged between 1 and 3 years-old. Diagnosis of LCH should be based on the synthetical analysis of clinical presentations, in addition to features of imaging and histopathology. Although certain cases regress spontaneously, other patients require systemic chemotherapy together with the administration of steroids. The present study reports the case of an infant with LDH with multisystem involvement, including that of the bone, skin, orbit, spleen and lungs. The patient received chemotherapy and obtained rapid improvement in the involved systems. A total of 2.5 years after completion of the therapy, the patient still remains in follow-up and no evidence of active disease has been noted.

show abstract

Biology of Langerhans Cells and Langerhans Cell Histiocytosis

Cited by 70 publications

References 235 publications

Recurrent BRAF mutations in Langerhans cell histiocytosis

Recurrent BRAF mutations in Langerhans cell histiocytosis

Somatic activating ARAF mutations in Langerhans cell histiocytosis

Langerhans cell histiocytosis with multisystem involvement in an infant: A case report

Contact Info

Product

Resources

About